News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
BHL will undertake the development and supply of these molecules
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
‘Unmask Anemia’ aims to simplify assessment of iron deficiency anemia risk with an easy online self-test based on common signs and symptoms
Subscribe To Our Newsletter & Stay Updated
